Biblio
“The Progression of Alzheimer's Disease: Are Fast Decliners Really Fast? A Four-Year Follow-Up.”, J Alzheimers Dis, vol. 57, no. 3, pp. 775-786, 2017.
, “Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1033-43, 2016.
, “Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1509-1516, 2018.
, “Dementia Care in Times of COVID-19: Experience at Fundació ACE in Barcelona, Spain.”, J Alzheimers Dis, vol. 76, no. 1, pp. 33-40, 2020.
, “Performance on Specific Cognitive Domains and Cause of Death: A Prospective Population-Based Study in Non-Demented Older Adults (NEDICES).”, J Alzheimers Dis, vol. 51, no. 2, pp. 533-44, 2016.
, “Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1179-87, 2016.
, “Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People.”, J Alzheimers Dis, vol. 49, no. 2, pp. 387-98, 2016.
, “Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals.”, J Alzheimers Dis, vol. 49, no. 2, pp. 493-502, 2016.
, “APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 79, no. 2, pp. 511-530, 2021.
, “Prognostic Significance of Mild Cognitive Impairment Subtypes for Dementia and Mortality: Data from the NEDICES Cohort.”, J Alzheimers Dis, vol. 50, no. 3, pp. 719-31, 2016.
, “Social Cognition Deficits: The Key to Discriminate Behavioral Variant Frontotemporal Dementia from Alzheimer's Disease Regardless of Amnesia?”, J Alzheimers Dis, vol. 49, no. 4, pp. 1065-74, 2016.
, “Trends, Predictors, and Outcomes of Healthcare Resources Used in Patients Hospitalized with Alzheimer's Disease with at Least One Procedure: The Nationwide Inpatient Sample.”, J Alzheimers Dis, vol. 57, no. 3, pp. 813-824, 2017.
, “ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.”, J Alzheimers Dis, vol. 79, no. 1, pp. 423-431, 2021.
, “Comparative Cognitive Effects of Choreographed Exercise and Multimodal Physical Therapy in Older Adults with Amnestic Mild Cognitive Impairment: Randomized Clinical Trial.”, J Alzheimers Dis, vol. 73, no. 2, pp. 769-783, 2020.
, “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
, “Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 185-193, 2018.
, “Neuropsychiatric Symptoms in Patients with Dementia Associated with Increased Psychological Distress in Caregivers During the COVID-19 Pandemic.”, J Alzheimers Dis, vol. 80, no. 4, pp. 1705-1712, 2021.
, “Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 81, no. 2, pp. 629-640, 2021.
, “Effects of a Physical Activity Program that Incorporates Exercises Targeting Balance, Strength, and Proprioception on Cognitive Functions and Physical Performance in Old Adults with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 96, no. 1, pp. 245-260, 2023.
, “Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
, “The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer's Disease During the COVID-19 Crisis.”, J Alzheimers Dis, vol. 76, no. 1, pp. 41-47, 2020.
, “Abnormalities of Cerebral Deep Medullary Veins on 7 Tesla MRI in Amnestic Mild Cognitive Impairment and Early Alzheimer's Disease: A Pilot Study.”, J Alzheimers Dis, vol. 57, no. 3, pp. 705-710, 2017.
, “Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.”, J Neuropathol Exp Neurol, vol. 70, no. 11, pp. 960-9, 2011.
, “A Novel Antibody Targeting Tau Phosphorylated at Serine 235 Detects Neurofibrillary Tangles.”, J Alzheimers Dis, vol. 61, no. 3, pp. 899-905, 2018.
, “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
,